MEB fee rate change as of January 2024

The Medicines Evaluation Board (MEB) increases the fee rates for authorisation applications, authorisation changes and the annual fees of human medicinal products. Fees for consultation procedures will also be increased.

Just like in the past years the MEB indexes the fee rates, because of the salary and price developments, in order to cover all costs. Based upon these developments a cost increase of 6.4% has been incorporated in the fee rates for the year 2024.